Navigation Links
TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
Date:11/12/2008

ations management, healthcare utilization and organizational planning at Bayer Corporation and Wyeth Pharmaceuticals (formerly Ayerst Laboratories). Ms. Graham holds a B.A. in biology from the University of Delaware and an M.B.A. from the University of Connecticut.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company contact: Investor contact:

Paul Schneider Rhonda Chiger

TorreyPines Therapeutics, Inc. Rx Communications Group

858-623-5665
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
2. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
5. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
6. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
7. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
8. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
11. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the six months ended June 30, 2014. ... dollars and presented under International Financial Reporting Standards ... , Announced top-line results related to the ... subjects enrolled in the Phase 2 iDEAL Study ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Intrinsic ... 13485:2003 certified, GAMP® 5 compliant imaging core lab, ... international Phase II clinical trial to assess a ... Throughout this trial, Intrinsic Imaging will provide comprehensive ... to, protocol and charter development, site qualification, site ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
(Date:8/28/2014)... , Aug. 28, 2014   SunTrust Robinson Humphrey ... industry veterans to its equity research team in ... ongoing expansion in equity research demonstrates our commitment ... insights to enhance their investment decision making," said ... STRH.  "We continue to make significant investments in ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... Holdings, Inc. (OTC Bulletin Board: ADLS ), announced ... discussing the Company,s 2010 fourth quarter and full-year financial results ... T. Flavin, Ph.D., Chairman & Chief Executive Officer, as well ... an update on the Company. A press release reporting the ...
... March 17, 2011 Delta Point, Inc., a consulting ... business relationships, has named Ed Weimer as Executive Account ... for his ability to highly motivate, develop and inspire ... strategic vision to contribute to the organization,s goals. ...
... SHANGHAI, March 17, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: ... leading developer, manufacturer and distributor of probiotics products in ... categories of strain formula supplied to Bright Dairy. ... formulas that it supplies to Bright Dairy, one of ...
Cached Biology Technology:Advanced Life Sciences to Host 2010 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 2Ed Weimer Joins Delta Point, Inc. as Executive Account Director 2China-Biotics Expands Product Supplied to Bright Dairy 2China-Biotics Expands Product Supplied to Bright Dairy 3
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... American College of Sports Medicine,s Conference on Integrative ... Miami, Florida. These awards are meant to ... scientists from underrepresented groups into the mainstream of ... participation of young scientists at the American College ...
(Date:8/28/2014)... Dyslexia, the most commonly diagnosed learning disability ... disability that occurs when the regions of the ... , The use of non-invasive functional neuroimaging tools ... in dyslexia. However, most prior work has focused ... leaving a gap in our understanding of how ...
(Date:8/28/2014)... could pose a significant health risk to people with asthma ... of Allergy and Clinical Immunology . , By critically reviewing ... research has found that the presence of several types of ... well as increasing the likelihood of developing the condition. , ... University of Exeter Medical School and is the first time ...
Breaking Biology News(10 mins):Dyslexic readers have disrupted network connections in the brain 2Indoor mold poses health risk to asthma sufferers 2
... A well-preserved fossil discovered in northeast China provides new ... species--the placental mammals. According to a paper published today ... new milestone in mammal evolution that was reached 35 million ... gap in the fossil record and helps to calibrate modern, ...
... This press release is available in French . ... the severity of brain damage after a stroke, according to a ... Jasna Kriz and Frdric Calon, showed that the extent of brain ... consumed DHA type omega-3s daily. Details of the study can be ...
... new method of single molecule DNA sequencing is being ... funding from the Biotechnology and Biological Sciences Research Council,s ... The aim of the research is to create novel ... strands. The human genome contains 3164.7 million nucleic ...
Cached Biology News:Fossil discovery represents new milestone in early mammal evolution 2Fossil discovery represents new milestone in early mammal evolution 3Omega-3s reduce stroke severity 2
... The Finnpipette BioControl multichannel ... features as the single ... handle fits allseven multichannel ... tip cone modules. Both ...
... to offer the ATTO-TAG series of ... primary amines. Developed by Novotny and ... reagents are similar to the important ... anthracene-2,3-dicarboxaldehyde, all of which are also ...
...
...
Biology Products: